Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Emanuela
Emanuela Boschi, Parma IT
| Patent application number | Description | Published |
|---|---|---|
| 20110158846 | APPARATUS AND METHOD FOR STERILIZING CONTAINER CLOSURES - An apparatus ( | 06-30-2011 |
Emanuela Chiappini, Offida (ap) IT
| Patent application number | Description | Published |
|---|---|---|
| 20100255326 | PRINTABLE GAS BARRIERS - A method is provided for enhancing the gas barrier properties of substrates such as materials used in packaging, by applying a composition comprising a vinyl alcohol/vinyl amide copolymer, a cross linker and, optionally, a diacrylate or other polyacrylate and a photo initiator to the material and curing the composition by irradiation with UV light, visible light, IR irradiation and/or electron beam or by exposure to heat. The method includes the optional step of subjecting the material to a low-temperature plasma discharge or a corona discharge prior to applying the composition. The method provides, for example, packaging materials, such as, flexible packaging materials such as plastic films producing packaging materials with excellent gas barrier properties, for example oxygen barrier properties, which are readily printed upon. | 10-07-2010 |
Emanuela Gancia, Harlow Essex GB
| Patent application number | Description | Published |
|---|---|---|
| 20110124622 | ISOINDOLONES DERIVATIVES AS MEK KINASE INHIBITORS AND METHODS OF USE - The invention relates to isoindolones of formula, (I) with anti-cancer and/or anti-inflammatory activity and more specifically with MEK kinase inhibitory activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth, treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions. | 05-26-2011 |
Emanuela Gancia, Harlow GB
| Patent application number | Description | Published |
|---|---|---|
| 20110118230 | DIAZACARBAZOLES AND METHODS OF USE - The invention relates to 1,7-diazacarbazole compounds of Formula (I), (I-a) and (I-b) which are useful as kinase inhibitors, more specifically useful as checkpoint kinase 1 (chk1) inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same to treat various forms of cancer and hyperproliferative disorders, as well as methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions. | 05-19-2011 |
| 20110124654 | DIAZACARBAZOLES AND METHODS OF USE - The invention relates to 1,5-diazacarbazole compounds of Formula (I), (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g) and (I-h) which are useful as kinase inhibitors, more specifically useful as checkpoint kinase 1 (chk1) inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same to treat various forms of cancer and hyperproliferative disorders, as well as methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions. | 05-26-2011 |
Emanuela Garcia, Royston GB
| Patent application number | Description | Published |
|---|---|---|
| 20090012134 | Arylsulfonyl Benzofused Heterocycles as 5-Ht2a Antagonists - Compounds of formula (I): are potent and selective antagonists of the 5-HT | 01-08-2009 |
Emanuela Grassilli, Monza IT
| Patent application number | Description | Published |
|---|---|---|
| 20100081704 | MODULATOR COMPOUNDS OF THE DRUG RESISTANCE IN EPITHELIAL TUMOUR CELLS - The use of compounds is described which are capable of functionally blocking at least one of the genes chosen from the group composed of EphA1, EphA2, EphA8, EphB2, CSF1R, VEGFR2, RAMP2, RAMP3, CLRN1, MAPK4, PIK3C2A, PIK3CG, GSK3alpha, GSK3beta, IRAK3, DAPK1, JAK1, PIM1, TRB3, BTG1, LATS1, LIMK2, MYLK, PAK1, PAK2, CDC2, BTK, PNRC2, NCOA4, NR2C1, TPR, RBBP8, TRPC7, FXYD1, ERN1, PRSS16, RPS3, CCL23 and SERPINE1, for the manufacture of a medicament destined to diminish the resistance to chemotherapeutic drugs in the therapeutic treatment of epithelial tumour pathologies. Also described is a method for the determination of the drug resistance in tumour cells, as well as a method for the identification of tumour stem cells. | 04-01-2010 |
Emanuela Izzo, Milano IT
| Patent application number | Description | Published |
|---|---|---|
| 20100210631 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS - Substituted 2-[2-(phenyl)ethylamino]alkaneamide derivatives, pharmaceutically acceptable salts thereof, and pharmaceutical compositions containing them are useful as sodium and/or calcium channel modulators for preventing, alleviating and curing pathologies wherein the above mechanisms play a pathological role. The compounds may be particularly used for the prevention, alleviation, and curing of, for example, neurological, cognitive, psychiatric, inflammatory, urogenital, and gastrointestinal diseases. | 08-19-2010 |
| 20110014304 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSYCHIATRIC DISORDERS - The disclosure relates to pharmacotherapy of a psychiatric disorder which is schizophrenia and/or anxiety, wherein schizophrenia includes schizophrenia related disorders such as brief psychotic disorders, delusional disorders, schizoaffective disorders, and schizophreniform disorders, and anxiety includes panic disorders, obsessive-compulsive disorders (OCD), post-traumatic stress disorders (PTSD), social phobia or social anxiety disorders, specific phobia, and generalized anxiety disorders (GAD). The compounds of the disclosure are useful for the treatment of the above psychiatric disorders alone or in combination with other therapeutical agents effective in the treatment of schizophrenia and/or anxiety disorders. | 01-20-2011 |
Emanuela Marcenaro, Genova-Pegli IT
| Patent application number | Description | Published |
|---|---|---|
| 20090208416 | MONOCLONAL ANTIBODIES AGAINST NKG2A - The present invention relates to methods of treating immune disorders, particularly autoimmune or inflammatory disorders, and methods of producing antibodies and other compounds for use in therapeutic strategies for treating such disorders. Generally, the present methods involve the use of antibodies or other compounds that prevent the stimulation of NKG2A receptors on NK cells, leading to the lysis of dendritic cells that contribute to the pathology of the disorders. | 08-20-2009 |
| 20110229486 | Monoclonal Antibodies Against NKG2A - The present invention relates to methods of treating immune disorders, particularly autoimmune or inflammatory disorders, and methods of producing antibodies and other compounds for use in therapeutic strategies for treating such disorders. Generally, the present methods involve the use of antibodies or other compounds that prevent the stimulation of NKG2A receptors on NK cells, leading to the lysis of dendritic cells that contribute to the pathology of the disorders. | 09-22-2011 |
Emanuela Martinuzzi, Paris Cedex 14 FR
| Patent application number | Description | Published |
|---|---|---|
| 20120094865 | Method for Stimulating Antigen-Specific T Cell Responses Using Accelerated Co-Cultured Dendritic Cells - The invention relates to a method for stimulating antigen-specific T cell responses by using accelerated co-cultured dendritic cells, and to uses thereof, such as a method for diagnosing a disease and a method for producing isolated T cell clones displaying specific immunological properties. | 04-19-2012 |
Emanuela Meiani, Rome IT
| Patent application number | Description | Published |
|---|---|---|
| 20090288101 | SERVICE EXCEPTION RESOLUTION FRAMEWORK - A service exception resolution framework provides a centralized exception handling console (EHC) used to reprocess unfulfilled service requests that have result in service request exceptions. The EHC allows an operator to analyze multiple service request exceptions simultaneously from disparate applications and domains. The framework greatly reduces the time, cost, and resource expenditures needed to analyze and resolve service request exceptions and reprocess service requests regardless of the applications and domains from which the service request exceptions result. | 11-19-2009 |
Emanuela Peschechera, Milan IT
| Patent application number | Description | Published |
|---|---|---|
| 20100029579 | ANTIVIRAL COMPOUNDS - The invention provides a new class of compounds exhibiting an inhibitory effect on neuraminidase (NA), hemagglutinin (HA) and structural M | 02-04-2010 |
Emanuela Tassoni, Ciampino IT
| Patent application number | Description | Published |
|---|---|---|
| 20090312286 | DERIVATIVES OF 4-TRIMETHYLAMMONIUM-3-AMINOBUTYRATE AND 4-TRIMETHYLPHOSPHONIUM-3-AMINOBUTYRATE AS CPT-INHIBITORS - The invention provides a new class of compounds capable of inhibiting carnitine palmitoyl transferase (CPT) having formula (I) | 12-17-2009 |
| 20110136905 | CRYSTALLINE TEGLICAR - The present invention relates to a new crystalline form of R-4-trimethylammonium-3-(tetradecylcarbamoyl)-amino butyrate (also named crystalline Form I of ST 1326 or teglicar), a process for its preparation and pharmaceutical compositions containing same. | 06-09-2011 |